Aileron Therapeutics, Inc. (ALRN): Price and Financial Metrics
ALRN Price/Volume Stats
|Current price||$1.60||52-week high||$9.36|
|Prev. close||$1.57||52-week low||$1.12|
|Day high||$1.60||Avg. volume||41,568|
|50-day MA||$1.44||Dividend yield||N/A|
|200-day MA||$2.68||Market Cap||7.26M|
ALRN Stock Price Chart Interactive Chart >
Aileron Therapeutics, Inc. (ALRN) Company Bio
Aileron Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, which represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The company's lead product candidate ALRN-6924 is being evaluated in multiple clinical trials. The company was founded in 2005 and is based in Cambridge, Massachusetts.
ALRN Latest News Stream
|Loading, please wait...|
ALRN Latest Social Stream
View Full ALRN Social Stream
Latest ALRN News From Around the Web
Below are the latest news stories about AILERON THERAPEUTICS INC that investors may wish to consider to help them evaluate ALRN as an investment opportunity.
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Cancer drugmaker down to 3 employees after trial failure
A cancer firm has gone from a paltry nine employees to an even scanter three after a chemoprotective drug failed in clinical trials.
Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall
Aileron Therapeutics (NASDAQ: ALRN) announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast cancer showed severe neutropenia (Grade 4) and alopecia (hair loss). The primary endpoint of the Phase 1b open-label trial was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, or "TAC" chemotherapy, was the duration and incidence of severe neutropenia
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint of the Phase 1b open-label trial, which was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, a
ALRN Price Returns
Loading social stream, please wait...